Winton Group LTD Cytokinetics Inc Transaction History

Winton Group LTD

$1.72 Billion
Q2 2025

A detailed history of Winton Group LTD transactions in Cytokinetics Inc stock. As of the latest transaction made, Winton Group LTD holds 28,159 shares of CYTK stock, worth $1.6 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

28,159

Previous 24,255 16.1%

Holding current value

$1.6 Million

Previous $974,000 4.52%

% of portfolio

0.05%

Previous 0.07%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$29.84 - $42.92 $116,495 - $167,559	3,904 Added 16.1%	28,159 $930,000
Q1 2025 May 15, 2025	BUY	$40.19 - $51.12 $210,997 - $268,380	5,250 Added 27.62%	24,255 $974,000
Q4 2024 Feb 12, 2025	BUY	$46.36 - $58.62 $426,975 - $539,890	9,210 Added 94.03%	19,005 $893,000
Q3 2024 Nov 12, 2024	SELL	$51.22 - $60.16 $427,891 - $502,576	-8,354 Reduced 46.03%	9,795 $517,000
Q2 2024 Aug 09, 2024	BUY	$47.86 - $75.05 $868,611 - $1.36 Million	18,149 New	18,149 $983,000
Q4 2023 Feb 12, 2024	BUY	$26.88 - $83.49 $472,980 - $1.47 Million	17,596 New	17,596 $1.47 Million
Q1 2023 May 12, 2023	BUY	$33.36 - $45.71 $33,360 - $45,710	1,000 Added 9.63%	11,380 $400,000
Q4 2022 Feb 14, 2023	BUY	$35.77 - $51.11 $121,725 - $173,927	3,403 Added 48.77%	10,380 $475,000
Q3 2022 Nov 10, 2022	SELL	$38.54 - $54.52 $11,446 - $16,192	-297 Reduced 4.08%	6,977 $338,000
Q2 2022 Aug 10, 2022	BUY	$33.93 - $48.92 $246,806 - $355,844	7,274 New	7,274 $286,000
Q1 2022 May 11, 2022	SELL	$29.74 - $46.0 $204,254 - $315,928	-6,868 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$34.35 - $46.38 $235,915 - $318,537	6,868 New	6,868 $313,000

Others Institutions Holding CYTK

# of Institutions

370

Shares Held

129M

Call Options Held

3.62M

Put Options Held

1.14M

View Full List

About CYTOKINETICS INC

Ticker CYTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,144,096
Market Cap $5.36B
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...

More about CYTK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Winton Group LTD with notifications on news.

Account